Everolimus Tablet Market Scope
Afinitor, generically available as Everolimus Tablets, is a prescription drug that is used to relieve the effects of Breast Cancer, Renal Cell Carcinoma, Advanced Neuroendocrine Tumors, Renal Angiomyolipoma, and Subependymal Giant Cell Astrocytoma. Everolimus is an immunosuppressant that prevents haematopoietic and nonhaematopoietic cells from proliferating in response to growth factors. Everolimus is associated with a lower occurrence of cytome-galovirus infection in cardiac and renal transplant recipients as compared to azathioprine and MMF. Multiple factors including prevalence of cancer and other renal infections have contributed to rising demand for Everolimus Tablets in different regions across the globe.
The Everolimus Tablet market study is segmented by Type (2.5 mg Tablets, 5 mg Tablets, 7.5 mg Tablets and 10 mg Tablets), by Application (Oncology, Organ transplant, Gastrointestinal and Others) and major geographies with country level break-up.
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Novartis AG (Switzerland), Biocon (India), Mylan N.V. (United States), Endo International plc (Ireland), Breckenridge Pharmaceutical (Germany), Glenmark Pharmaceuticals Limited (India), Natco Pharma (India), Cipla Limited (India), Dr. Reddy's Laboratories (India) and Concord Biotech Limited (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Hikma Pharmaceuticals PLC (United Kingdom), Panacea Biotec (India), Lexicare Pharma Pvt. Ltd. (India) and Taj Pharmaceuticals Limited (India).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global Everolimus Tablet market by Type, Application and Region.
On the basis of geography, the market of Everolimus Tablet has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
On 8th March, 2021 - Natco Pharma Limited Announced Final FDA Approval of its Abbreviated New Drug Application (ANDA) for Everolimus Tablets (Generic Version of “Afinitor”). The Product Was Developed in Collaboration with Breckenridge Pharmaceutical, Inc. The Tablets will be Available in 2.5mg, 5mg and 7.5mg Strengths in A Blister Card Packaging Configuration. and On 10th December, 2019 - Endo Launched Generic Version of Afinitor (Everolimus) Tablets for the United States Market, through its Subsidiary Firm Par Pharmaceuticals. The Launch is Aimed to Cater to Rapid Growing Demand for Afinitor Based on its Sales Data along with Other Key Strategic Factors.
- High Investments in Research & Development
- Prevalence of Cancer and Renal Disorders
- Rising Geriatric Population
- Technical Progress in Pharmaceutical Industry
- Growing Healthcare Infrastructure Due to Pandemic
- Side Effects and Adverse Reactions
- Lack of Trained Professionals
- Lack of Regulatory Mechanism in Specific Regions
Key Target AudienceEverolimus Tablet Manufactures, New Entrants and Investors, Everolimus Tablet Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Frequently Asked Questions (FAQ):
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Everolimus Tablet Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.